Drugs / TAO1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01651715 | Sep 2012 → Aug 2013 | common cold | Theranor s.p.r.l | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAO1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01651715 ↗ |
| Action | Inhibit | “anti-TLR3” NCT01651715 ↗ |
| Modality | Protein / enzyme biologic | “oral antibodies to the TLR3 FYW peptide” NCT01651715 ↗ |
| Route | Oral | “TAO1 tablets (to be dissolved in the mouth, not to be swallowed” NCT01651715 ↗ |
| Target | TLR3 | “anti-TLR3” NCT01651715 ↗ |